Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 18/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1820324 | 0.92 | ADORA1 (0.51) | ADORA1ADORA3KDM4EADORA2BADORA2A | |
| SCHEMBL1810364 | 0.91 | ADORA1 (0.52) | ADORA1ADORA3KDM4EADORA2BADORA2A | |
| SCHEMBL1811451 | 0.91 | ADORA1 (0.52) | ADORA1ADORA3KDM4EADORA2BADORA2A | |
| SCHEMBL1814361 | 0.88 | ADORA1 (0.46) | ADORA1ADORA3KDM4EADORA2BADORA2A | |
| SCHEMBL5175531 | 0.87 | ADORA1 (0.75) | ADORA1ADORA3KDM4EADORA2BADORA2A | |
| SCHEMBL1817175 | 0.85 | ADORA1 (0.45) | ADORA1ADORA3KDM4EADORA2BALDH1A1 | |
| SCHEMBL1817001 | 0.84 | ADORA1 (0.48) | ADORA1ADORA3ADORA2BALDH1A1 | |
| SCHEMBL1819128 | 0.83 | ADORA1 (0.67) | ADORA1ADORA3KDM4EADORA2BADORA2A | |
| SCHEMBL3305543 | 0.81 | ADORA1 (0.64) | ADORA1ADORA3ADORA2BADORA2A | |
| SCHEMBL1812448 | 0.81 | ADORA1 (0.64) | ADORA1ADORA3ADORA2BADORA2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2321296-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-05-18 | — | — | EP | disclosed |
| US-20100099681-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-22 | — | — | US | disclosed |
| WO-2010020363-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-02-25 | — | — | WO | disclosed |
| EP-1750698-A2 | 5-ANILINO-4-HETEROARYLPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES | Bayer Pharmaceuticals Corporation (US) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005112923-A2 | 5-ANILINO-4-HETEROARYLPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099681-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | CYP3A5, ABAT, TPMT | ADORA1 724/4885ADORA3 168/4885KDM4E 2516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.